GNAI1 and breast carcinoma: For instance, low GNAI2 expression correlates with trastuzumab resistance in HER2-positive breast cancer [24], while GNAI1 overexpression has been linked to poor survival and chemoresistance in advanced-stage ovarian tumors [25].